Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
Stock Symbol: REGN
Stock Exchange: NASDAQ
Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.
Learn more about how our team produces the highest-quality treatments for patients at https://www.regeneron.com/.
992 articles with Regeneron Pharmaceuticals, Inc.
Bayer HealthCare AG And Regeneron Pharmaceuticals, Inc. To Collaborate On VEGF Trap For The Treatment Of Eye Diseases; Regeneron Retains U.S. Commercialization Rights, Receives $75 Million Upfront, And Eligible For Up To $245 Million Of Milestone Payments
Regeneron Pharmaceuticals, Inc. Names Peter Powchik, M.D., Senior Vice President Of Clinical Development
Regeneron Pharmaceuticals, Inc. Announces Presentation At UBS Warburg Global Life Sciences Conference
National Institutes of Health (NIH) Selects Regeneron Pharmaceuticals, Inc. For Knockout Mouse Project; Regeneron Pharmaceuticals, Inc. Will Use Its VelociGene(R) Technology To Target 3,500 Genes Over Five Years, Providing New Models Of Human Diseases
Regeneron Pharmaceuticals, Inc. Reports Second Quarter Financial And Operating Results; BLA Filing For Auto-Inflammatory Diseases Planned For Early 2007; Two Antibody Candidates From VelocImmune(R) Program To Enter Clinical Trials Each Year Beginning In 2
Regeneron Pharmaceuticals, Inc. Receives Fast-Track Designation For The IL-1 Trap In CIAS1-Associated Periodic Syndromes (CAPS)
Regeneron Pharmaceuticals, Inc. Reports Positive Phase 1 Data For The VEGF Trap In Age-Related Macular Degeneration
Sanofi-Aventis (France) And Regeneron Pharmaceuticals, Inc. Expand Their VEGF Trap Oncology Collaboration To Japan; Regeneron To Receive $25 Million